Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Bristol-Myers’ Schizophrenia Drug Falls Short in Key Trial

Daniel Kim Views  

Shutterstock
Shutterstock

Bristol-Myers Squibb (BMS) recently revealed that a late-stage clinical trial for the expanded use of its medication, Cobenfy, did not yield statistically significant results.

According to reports, the medication, which was approved last year, failed to meet its primary objective in this trial involving schizophrenia patients who did not improve with current antipsychotic therapies.

At week six of the trial, the medication demonstrated a 2 percentage point drop in a symptom severity measure compared to a placebo.

Bristol-Myers has completed the analysis of all trial data and intends to present the findings in depth at a future academic conference.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • 3 Daily Habits That Might Be Aging Your Brain Faster Than You Think
  • The One-Spoon Habit That’s Taking Over Healthy Mornings
  • Tired of Painful Periods? Your Pantry Might Hold the Cure
  • Still Tired After 8 Hours of Sleep? This Could Be Why
  • Scientists Link Let-7 Gene to Lung Healing—and Possibly a Cure for Fibrosis
  • GLP-1 Drugs Like Ozempic Might Cut Cancer Risk Too, Study Finds

Share it on...